Engineered peptides show promise in cancer immunotherapy

FHS
April 22, 2024
11:49 am

In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.

Dr. Robin Carhart-Harris | Center for Psychedelic Research, Imperial College | Psychedelic Finance

What do you believe is the most important thing for people to understand about the future of psychedelics as medicine? ‍‍Probably that all of the

July 7, 2023

At BIO, signs Congress’ tough stance on China is chilling biotech relationships

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a

June 6, 2024

Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares | Psychedelic Invest

VANCOUVER, BC, June 12, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today

June 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.